<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241681</url>
  </required_header>
  <id_info>
    <org_study_id>14.22.MET</org_study_id>
    <nct_id>NCT02241681</nct_id>
  </id_info>
  <brief_title>Medium Chain Triglycerides Plasma Profile and Their Metabolites After Oral Peptamen Intake</brief_title>
  <official_title>Medium Chain Triglycerides Plasma Profile and Their Metabolites After Oral Peptamen Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medium Chain Triglycerides (MCT) have been used for many years as a good source of lipid to&#xD;
      decrease potential for fat malabsorption. However, the pharmacokinetics of MCT and of their&#xD;
      metabolites have not been explored in details.&#xD;
&#xD;
      This is an exploratory study aiming at determining the plasma level of MCT and their&#xD;
      metabolites after oral intake of Peptamen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 subjects will be given 250mL of peptamen 1.5 twice, with 4 hours of interval, on a single&#xD;
      day.&#xD;
&#xD;
      Plasma kinetics of MCTs and their metabolites will be made over 8 hours from baseline&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of plasma Medium Chain Triglycerides (MCT)</measure>
    <time_frame>over 8 hours post intake</time_frame>
    <description>Tmax, Cmax and AUC for MCTs as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of plasma MCT metabolites such as free fatty acids</measure>
    <time_frame>over 8 hours post intake</time_frame>
    <description>Tmax, Cmax and AUC for MCT metabolites as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Peptamen 1.5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>500 mL of Peptamen 1.5</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Peptamen 1.5</intervention_name>
    <description>Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.</description>
    <arm_group_label>Peptamen 1.5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females&#xD;
&#xD;
          -  Aged between 20 and 65 years old&#xD;
&#xD;
          -  BMI in the normal range (18.5 to 25.0 kg/m2)&#xD;
&#xD;
          -  Having signed his/her consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant digestive (including malabsorption or major surgery), renal,&#xD;
             hepatic, pancreatic or metabolic disease (diabetes, hypo or hyperthyroidism, hypo or&#xD;
             hypercorticism), as determined by the medical (screening) visit and a standard blood&#xD;
             chemistry analysis (glucose, total cholesterol, ALDL, AHDL, triglycerides, ASAT, ALTI,&#xD;
             gamma GT, RCRP, creatinine)&#xD;
&#xD;
          -  Medically diagnosed anemia based on a blood formula&#xD;
&#xD;
          -  Food allergy, lactose intolerance and intolerance to milk proteins (anamnesis)&#xD;
&#xD;
          -  Smokers (anamnesis)&#xD;
&#xD;
          -  Pregnancy (anamnesis)&#xD;
&#xD;
          -  Under corticoids or hormone (adrenal, thyroid) treatment&#xD;
&#xD;
          -  Alcohol intake: &gt; 2 units a day (anamnesis)&#xD;
&#xD;
          -  Consumption of illicit drugs (anamnesis)&#xD;
&#xD;
          -  Having given blood within the last month, or willing to make a blood donation until&#xD;
             one month following the end of the study&#xD;
&#xD;
          -  Subject who cannot be expected to comply with the study procedures, including&#xD;
             consuming the test product&#xD;
&#xD;
          -  Currently participating or having participated in another clinical trial during the&#xD;
             last month prior to the beginning of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Beaumont, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metabolic Unit, Clinical Development Unit,Nestec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic unit, clinical Development unit, Nestec</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medium Chain Triglycerides</keyword>
  <keyword>Medium Chain Triglycerides metabolites</keyword>
  <keyword>Peptamen 1.5</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

